On the other hand, a recent study has reported that increased TIMP-2 expression in the stromal compartment, but not in tumor cells, is associated with an enhanced response to cisplatin and paclitaxel-based chemotherapy in ovarian cancer patients [189]. The gene discussed is TIMP2; the disease is ovarian carcinoma.